دورية أكاديمية

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia

التفاصيل البيبلوغرافية
العنوان: IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
المؤلفون: Cerchione C., Romano A., Daver N., DiNardo C., Jabbour E. J., Konopleva M., Ravandi-Kashani F., Kadia T., Martelli M. P., Isidori A., Martinelli G., Kantarjian H.
المساهمون: Cerchione, C., Romano, A., Daver, N., Dinardo, C., Jabbour, E. J., Konopleva, M., Ravandi-Kashani, F., Kadia, T., Martelli, M. P., Isidori, A., Martinelli, G., Kantarjian, H.
سنة النشر: 2021
المجموعة: IRIS Università degli Studi di Perugia
مصطلحات موضوعية: acute myeloid leukemia, AML, enasidenib, IDH, isocitrate dehydrogenase, ivosidenib, target therapy
الوصف: Recently, the discovery of biological and clinical properties of mutated isoforms 1 and 2 mutations of isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with acute myeloid leukemia (AML), lead to the development of an individualized treatment strategy. Promoting differentiation and maturation of the malignant clone targeting IDH is an emerging strategy to promote clinical responses in AML. Phase I/II trials have shown evidence of safety, tolerability, and encouraging evidence of efficacy of two small molecule inhibitors targeting IDH2 and IDH1 gene mutations, respectively enasidenib and ivosidenib. In this review, the contribution of IDH1/IDH2 mutations in leukemogenesis and progress of targeted therapeutics in AML will be highlighted.
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33898313; info:eu-repo/semantics/altIdentifier/wos/WOS:000642601900001; volume:11; firstpage:639387; journal:FRONTIERS IN ONCOLOGY; http://hdl.handle.net/11391/1505026Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85105008222
DOI: 10.3389/fonc.2021.639387
الإتاحة: https://doi.org/10.3389/fonc.2021.639387Test
http://hdl.handle.net/11391/1505026Test
رقم الانضمام: edsbas.6FFCE4A7
قاعدة البيانات: BASE